Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BetterLife Pharma Inc C.BETR

Alternate Symbol(s):  BETRF

Healthcare
BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as... see more

Recent & Breaking News (CSE:BETR)

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

GlobeNewswire August 24, 2022

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

GlobeNewswire July 6, 2022

BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference

GlobeNewswire June 23, 2022

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

GlobeNewswire June 21, 2022

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference

GlobeNewswire April 21, 2022

BetterLife's BETR-001 Demonstrates BETR-001 Anti-depressant Activity in Preclinical Models of Depression

GlobeNewswire April 6, 2022

BetterLife Obtains In Vivo PK Data for BETR-001 Confirming its Bioavailability in Brain

GlobeNewswire March 16, 2022

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model

GlobeNewswire February 15, 2022

BetterLife Launches New Corporate Website

GlobeNewswire February 10, 2022

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001

GlobeNewswire January 20, 2022

BetterLife (CSE:BETR) advances non-hallucinogenic psychedelic treatment BETR-001

Julia Kennedy  January 18, 2022

BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001

GlobeNewswire January 18, 2022

Dr. Eleanor Fish, Advisory Board Member, Awarded Order of Canada

GlobeNewswire January 6, 2022

BetterLife’s (CSE:BETR) Altum Pharmaceuticals secures financing commitment

Brieanna McCutcheon  December 22, 2021

IIROC Trade Resumption - BETR

PR Newswire December 22, 2021

BetterLife's Wholly-Owned Subsidiary, Altum Pharmaceuticals, Obtains Non-Dilutive Financing Commitment From Strategic Investor!

GlobeNewswire December 22, 2021

IIROC Trading Halt - BETR

PR Newswire December 22, 2021

BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression

GlobeNewswire December 9, 2021

H.C. Wainwright 2nd Annual Psychedelics Conference, BACK TO THE FUTURE!

GlobeNewswire December 3, 2021

BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile

GlobeNewswire November 29, 2021